Gilead’s Yescarta (CAR-T) obtains marketing approval in Europe

Gilead announced today, before trading started in Wall Street, that the European Commission has granted marketing approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with DLBCL (diffuse large B cell lymphoma) and PMBCL (primary mediastinal B-cell lymphoma). It is the first CAR-T therapy that has obtained approval in Europe for two aggressive types of non Hodgkin lymphoma. Importantly, Yescarta had already been approved by the FDA on October 18, 2017. Gilead’s shares  today have risen 1.67%.

(Source: Gilead)